CTOs on the Move

Seqirus

www.seqirus.com

 
Seqirus, part of the CSL Group, is the new global company created from the combined strength and expertise of bioCSL and the influenza vaccines business formerly owned by Novartis. In July 2015, the two businesses joined forces to create Seqirus, now the second largest influenza vaccine company in the world. With extensive research and production expertise and manufacturing plants in the US, UK, Germany and Australia, Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention and control of influenza globally. Seqirus has a workforce of over 2,000 employees, significant manufacturing capacity and a ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.seqirus.com
  • 475 Green Oaks Parkway
    Holly Springs, NC USA 27540
  • Phone: 919.577.5000

Executives

Name Title Contact Details

Similar Companies

National Institute of Clinical Research

National Institute of Clinical Research is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ferndale Laboratories

Perhaps the most important decision in determining the destiny of Ferndale Laboratories, Inc. was made in the Fall of 1975. At that time, Ferndale Laboratories, Inc. embarked on a mission to grow from a local pharmaceutical manufacturer to a company with

Galectin Therapeutics

Galectin Therapeutics (NASDAQ: GALT) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on the Company`s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function.

Essential Formulas

Essential Formulas is a Dallas, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals is a clinical stage, Nasdaq listed (ticker ARWR) company developing medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, our therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Our RNAi-based therapeutics are at the leading edge of genetic-based therapy with the potential to bring life changing treatments for patients. Our Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. The TRiM platform builds on more than a decade of work on actively targeted drug delivery and offers several advantages including simplified manufacturing and reduced costs; multiple routes of administration; and potential for improved safety. Our employees are nimble, science-driven, and innovative professionals. A career at Arrowhead offers the opportunity to collaborate with top notch scientists to rapidly discover and develop RNAi-based therapeutics to add to our growing pipeline. Research and development activities are located in Madison, WI. Our R&D group includes fully-integrated capabilities for chemistry, biology, and toxicology. Madison is an exciting and sophisticated city that includes state government, the flagship campus of the University of Wisconsin, and major research organizations. Our HQ, clinical and regulatory operations are located in Pasadena, CA. Just north of Los Angeles and resting in the foothills of the San Gabriel Mountains, Pasadena is known for its natural scenic beauty, vibrant cultural and academic environment and rich architectural setting.